Literature DB >> 29368338

Quantitative proteomics reveals that miR-222 inhibits erythroid differentiation by targeting BLVRA and CRKL.

Li Jiang1, Xing Wang1, Yong Wang1, Xiaoyan Chen1.   

Abstract

miR-222 plays an important role in erythroid differentiation, but the potential targets of miR-222 in the regulation of erythroid differentiation remain to be determined. The target genes of miR-222 were identified by proteomics combined with bioinformatics analysis in this study. Thirteen proteins were upregulated, and 13 were downregulated in K562 cells following transfection with miR-222 inhibitor for 24 and 48 hours. Among these proteins, BLVRA and CRKL were upregulated after transfection of miR-222 inhibitor in K562 cells and human CD34+ HPCs. Moreover, miR-222 mimics reduced and miR-222 inhibitor enhanced the mRNA and protein levels of both BLVRA and CRKL. Luciferase assay showed that miR-222 directly targeted 3'-UTR of BLVRA and CRKL. In addition, overexpression of either BLVRA or CRKL or both increased the erythroid differentiation of K562 cells, while silencing of either BLVRA or CRKL or both by siRNA significantly attenuated hemin-induced erythroid differentiation of K562 cells. Our results indicated that BLVRA and CRKL are targets of miR-222.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  BLVRA; CRKL; erythropoiesis; miR-222; microRNA

Mesh:

Substances:

Year:  2018        PMID: 29368338     DOI: 10.1002/cbf.3321

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  3 in total

1.  Targeting of CDKN1B by miR-222-3p may contribute to the development of intervertebral disc degeneration.

Authors:  Jianwei Liu; Jia Yu; Weiping Jiang; Maolin He; Jinmin Zhao
Journal:  FEBS Open Bio       Date:  2019-03-12       Impact factor: 2.693

2.  Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy.

Authors:  Shan Zhang; Yaohui Wang; Yan Wang; Jing Peng; Chenwei Yuan; Liheng Zhou; Shuguang Xu; Yanping Lin; Yueyao Du; Fan Yang; Jie Zhang; Huijuan Dai; Wenjin Yin; Jinsong Lu
Journal:  Front Oncol       Date:  2020-04-28       Impact factor: 6.244

3.  Long-Term Effects of Biliverdin Reductase a Deficiency in Ugt1-/- Mice: Impact on Redox Status and Metabolism.

Authors:  Giulia Bortolussi; Xiaoxia Shi; Lysbeth Ten Bloemendaal; Bhaswati Banerjee; Dirk R De Waart; Gabriele Baj; Weiyu Chen; Ronald P Oude Elferink; Ulrich Beuers; Coen C Paulusma; Roland Stocker; Andrés F Muro; Piter J Bosma
Journal:  Antioxidants (Basel)       Date:  2021-12-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.